Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Gastrointestinal 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2CNS 2Thoracic 1Myeloid 1Genitourinary 1Endocrine 1Breast 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 547Pemetrexed 402Cisplatin 400Paclitaxel 272Docetaxel 255Gemcitabine 218pembrolizumab 190Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 179Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 106atezolizumab 92Gefitinib 74Radiosurgery 71anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 49Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Microarray Analysis × Thoracic × Clear all
NCT00057798 2011-03-08

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Roswell Park Cancer Institute

Phase 2 Completed
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡